References
- Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol 2015; 62: S121-30. doi: 10.1016/j.jhep.2015.01.003
- de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension. J Hepatol 2015; 63: 743-52. doi: 10.1016/j.jhep.2015.05.022
- Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50: 923-8. doi: 10.1016/j.jhep.2009.01.014
- Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, García-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2022; 76: 681-93. doi: 10.1016/J.JHEP.2021.11.018
- Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019
- Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012; 57: 421-9. doi: 10.1016/j.jhep.2012.01.031
- Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging – correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-26. doi: 10.1148/radiol.10092214
- Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013; 267: 776-86. doi: 10.1148/radiol.13120775
- Ricke J, Seidensticker M. Molecular imaging and liver function assessment by hepatobiliary MRI. J Hepatol 2016; 65: 1081-2. doi: 10.1016/j. jhep.2016.10.004
- Kukuk GM, Schaefer SG, Fimmers R, Hadizadeh DR, Ezziddin S, Spengler U, et al. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol 2014; 24: 2482-90. doi: 10.1007/s00330-014-3291-x
- Kobi M, Paroder V, Flusberg M, Rozenblit AMM, Chernyak V. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase? Clin Radiol 2017; 72: 55-62. doi: 10.1016/j. crad.2016.10.004
- Okada M, Murakami T, Kuwatsuru R, Nakamura Y, Isoda H, Goshima S, et al. Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter study. Radiology 2016; 281: 474-83. doi: 10.1148/ radiol.2016151061
- Zhang W, Wang X, Miao Y, Hu C, Zhao W. Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla. Abdom Radiol 2018; 43: 2262-9. doi: 10.1007/s00261-018-1462-y
- Öcal O, Peynircioglu B, Loewe C, van Delden O, Vandecaveye V, Gebauer B, et al. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. Eur Radiol 2021; 32: 1320-9. doi: 10.1007/s00330-021-08218-9
- Liang M, Zhao J, Xie B, Li C, Yin X, Cheng L, et al. MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function. Eur J Radiol 2016; 85: 546-52. doi: 10.1016/j.ejrad.2015.12.015
- Ippolito D, Famularo S, Giani A, Orsini EB, Pecorelli A, Pinotti E, et al. Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI. Dig Liver Dis 2019; 51: 1438-45. doi: 10.1016/J.DLD.2019.04.009
- Yoon JH, Choi JI, Jeong YY, Schenk A, Chen L, Laue H, et al. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol 2016; 65: 1155-62. doi: 10.1016/j.jhep.2016.07.024
- Yoon JH, Lee JM, Kang H, Ahn SJ, Yang H, Kim E, et al. Quantitative assessment of liver function by using Gadoxetic Acid-enhanced MRI: hepatocyte uptake ratio. Radiology 2019; 290: 125-33. doi: 10.1148/radiol.2018180753
- Yamada S, Shimada M, Morine Y, Imura S, Ikemoto T, Saito Y, et al. A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging. PLoS One 2019; 14: e0210579. doi: 10.1371/journal.pone.0210579
- Notake T, Shimizu A, Kubota K, Ikehara T, Hayashi H, Yasukawa K, et al. Hepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancy. BJS Open 2021; 55(4): zraa048. doi: 10.1093/BJSOPEN/ZRAA048
- Daire JL, Leporq B, Vilgrain V, Van Beers BE, Schmidt S, Pastor CM. Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes. Eur J Drug Metab Pharmacokinet 2017; 42: 657-67. doi: 10.1007/s13318-016-0382-x
- Ayuso C, Forner A, Darnell A, Rimola J, García-Criado Á, Bianchi L, et al. Prospective evaluation of gadoxetic-acid MR for the diagnosis of HCC in newly detected nodules ≤ 2 cm in cirrhosis. Liver Int 2019; 39: 1281-91. doi: 10.1111/liv.14133
- Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012; 56: 103-8. doi: S0168-8278(11)00606-4 [pii] 10.1016/j.jhep.2011.06.027
- Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 2016; 26: 921-31. doi: 10.1007/ s00330-015-3900-3
- Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we? J Magn Reson Imaging 2017; 45: 646-59. doi: 10.1002/jmri.25518
- Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011; 29: 1047-52. doi: 10.1016/j.mri.2011.05.007
- Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, et al. Staging hepatic fibrosis: comparison of Gadoxetate Disodium-enhanced and diffusion-weighted MR imaging – preliminary observations. Radiology 2011; 259: 142-50. doi: 10.1148/radiol.10100621
- Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol 2017; 42: 179-90. doi: 10.1007/s00261-016-0841-5
- Vietti Violi N, Taouli B. Abbreviated MRI for HCC surveillance: is it ready for clinical use? Eur Radiol 2020; 30: 4147-9. doi: 10.1007/s00330-020-06904-8
- Canellas R, Rosenkrantz AB, Taouli B, Sala E, Saini S, Pedrosa I, et al. Abbreviated MRI protocols for the abdomen. Radiographics 2019; 39: 744-58. doi: 10.1148/rg.2019180123
- Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021; 31: 5615-28. doi: 10.1007/S00330-020-07637-4
- Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, et al. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 2012; 27: 301-6. doi: 10.2133/ dmpk.dmpk-11-rg-077
- Thakkar N, Slizgi JR, Brouwer KLR. Effect of liver disease on hepatic transporter expression and function. J Pharm Sci 2017; 106: 2282-94. doi: 10.1016/j.xphs.2017.04.053
- Shin NY, Kim MJ, Lim JS, Park MS, Chung YE, Choi JY, et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 2012; 22: 864-71. doi: 10.1007/ s00330-011-2333-x
- Yoneda N, Matsui O, Ikeno H, Inoue D, Yoshida K, Kitao A, et al. Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging 2015; 40: 3099-103. doi: 10.1007/s00261-015-0503-z
- Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, et al. Effects of portal hypertension on Gadoxetic Acid-Enhanced liver magnetic resonance: diagnostic and prognostic implications. Invest Radiol 2017; 52: 462-9. doi: 10.1097/RLI.0000000000000366
- Hectors SJ, Bane O, Kennedy P, Cuevas J, Thung S, Fischman A, et al. Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen. Eur Radiol 2021; 31: 4804-12. doi: 10.1007/s00330-020-07495-0
- Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014; 273: 30-50. doi: 1148/ radiol.14132362
- Renzulli M, Golfieri R, Bologna Liver Oncology Group (BLOG). Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. J Gastroenterol Hepatol 2016; 31: 69-80. doi: 10.1111/jgh.13150
- Renzulli M, Biselli M, Brocchi S, Granito A, Vasuri F, Tovoli F, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 2018; 67: 1674-82. doi: 10.1136/ gutjnl-2017-315384
- Ding Y, Rao SX, Chen C, Li R, Zeng MS. Assessing liver function in patients with HBV-related HCC: a comparison of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI. Eur Radiol 2015; 25: 1392-8. doi: 10.1007/ s00330-014-3542-x
- Haimerl M, Verloh N, Zeman F, Fellner C, Müller-Wille R, Schreyer AG, et al. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 2013; 8: e85658 doi: 10.1371/JOURNAL.PONE.0085658